Rest Of Europe Autologous Stem Cell & Non-stem Cell Therapies Market (2024-2029)

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the autologous stem cell & non-stem cell therapies market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources used for this study include National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), International Society for Stem Cell Research (ISSCR). Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); company websites; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global autologous stem cell and non-stem cell therapies market, which was validated through primary research.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information and assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

*Others include sales managers, marketing managers, and product managers.

Note: Tiers are defined based on a company’s total revenue. As of 2021, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the autologous stem cell & non-stem cell therapies market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

• The key players in the industry and market have been identified through extensive secondary research.
• The revenues generated from the autologous stem cell & non-stem cell therapies business of leading players have been determined through primary and secondary research.
• All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Bottom up Approach-

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach-

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Autologous stem cell and non-stem cell-based therapies involve the use of the patient's cells (stem and non-stem cells) for the development of therapeutic products. These cells are extracted, expanded, modified, and reintroduced back into the patient to address various medical conditions such as cancers, autoimmune diseases, and neurodegenerative disorders among others, serving as a novel approach to personalized medicine.

Key Stakeholders

• Stem Cell and Non-Stem Cell-based Therapeutic Product Manufacturing Companies
• Healthcare Service Providers (Including Hospitals and Diagnostic Centers)
• Pharmaceutical Product Manufacturing Companies
• National and Regional Research Boards and Organizations
• Research and Development Companies
• Clinical Research Organizations (CROs)
• Clinical Development and Manufacturing Organizations (CDMOs)
• Research Laboratories and Academic Institutes
• Market Research and Consulting Firms
• Cell and Gene Therapy Associations and Organizations

Report Objectives

• To define, describe, and forecast the autologous stem cell and non-stem cell-based therapies by type, indication, source, end-user, and region.
• To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
• To analyze micro-markets1 with respect to individual growth trends, prospects, and contributions to the overall autologous stem cell and non-stem cell-based therapies market.
• To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders.
• To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa
• To profile the key players in the global autologous stem cell and non-stem cell based therapies market as well as comprehensively analyze their core competencies2 and market rankings.
• To track and analyze competitive developments, such as product launches, pipeline products, partnerships, agreements, collaborations, expansions, and strategic alliances.
• To benchmark players within the market using the proprietary “Competitive Leadership Mapping” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

Company Information

• An additional two company profiles